New 2025 Research: Weight-Loss Drug Retatrutide May Reduce Obesity-Related Cancer Risk — What Patients Need to Know

2025 peer-reviewed research from Nature Portfolio shows retatrutide (LY3437943), a triple incretin agonist targeting GLP-1, GIP, and glucagon receptors, reduced obesity-related tumor growth up to 14-fold in pre-clinical models. Learn what this means for GLP-1 patients, FDA approval timeline (expected June 2025), and why metabolic health matters beyond weight loss. South Florida Trim Clinic — Naples FL telehealth weight loss clinic.

South Florida Trim Clinic provides physician-directed telehealth care from Naples, Florida.